0.019070 0.000000 0.008642 0.000000 0.022765 0.000000 0.000000 0.000000 0.020684 0.00000 0.00000 0.00000 Murray, C.W. Carr, M.G. Callaghan, O. Chessari, G. Congreve, M. Cowan, S. Coyle, J.E. Downham, R. Figueroa, E. Frederickson, M. Graham, B. McMenamin, R. O'Brien, M.A. Patel, S. Phillips, T.R. Williams, G. Woodhead, A.J. Woolford, A.J.A. http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic 2 90.00 114.38 90.00 52.439 43.928 53.080 C3 H7 N O2 89.093 y ALANINE L-peptide linking C6 H15 N4 O2 1 175.209 y ARGININE L-peptide linking C4 H8 N2 O3 132.118 y ASPARAGINE L-peptide linking C4 H7 N O4 133.103 y ASPARTIC ACID L-peptide linking C5 H10 N2 O3 146.144 y GLUTAMINE L-peptide linking C5 H9 N O4 147.129 y GLUTAMIC ACID L-peptide linking C2 H5 N O2 75.067 y GLYCINE peptide linking C6 H10 N3 O2 1 156.162 y HISTIDINE L-peptide linking H2 O 18.015 WATER non-polymer C6 H13 N O2 131.173 y ISOLEUCINE L-peptide linking C6 H13 N O2 131.173 y LEUCINE L-peptide linking C6 H15 N2 O2 1 147.195 y LYSINE L-peptide linking C5 H11 N O2 S 149.211 y METHIONINE L-peptide linking C9 H11 N O2 165.189 y PHENYLALANINE L-peptide linking C5 H9 N O2 115.130 y PROLINE L-peptide linking C3 H7 N O3 105.093 y SERINE L-peptide linking C4 H9 N O3 119.119 y THREONINE L-peptide linking C11 H12 N2 O2 204.225 y TRYPTOPHAN L-peptide linking C9 H11 N O3 181.189 y TYROSINE L-peptide linking C5 H11 N O2 117.146 y VALINE L-peptide linking C11 H10 Cl N3 O 235.670 4-CHLORO-6-(2-METHOXYPHENYL)PYRIMIDIN-2-AMINE non-polymer US J.Med.Chem. JMCMAR 0151 0022-2623 53 5942 10.1021/JM100059D 20718493 Fragment-Based Drug Discovery Applied to Hsp90. Discovery of Two Lead Series with High Ligand Efficiency. 2010 1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 100 1 SINGLE WAVELENGTH M x-ray 1 1.5418 1.0 1.5418 ROTATING ANODE 27959.336 HEAT SHOCK PROTEIN HSP 90-ALPHA RESIDUES 9-236 1 man polymer 235.670 4-CHLORO-6-(2-METHOXYPHENYL)PYRIMIDIN-2-AMINE 1 syn non-polymer 18.015 water 113 nat water HEAT SHOCK 86 KDA, HSP86, RENAL CARCINOMA ANTIGEN NY-REN-38HSP90 no no MGSSHHHHHHSSGLVPRGSHMDQPMEEEEVETFAFQAEIAQLMSLIINTFYSNKEIFLRELISNSSDALDKIRYESLTDP SKLDSGKELHINLIPNKQDRTLTIVDTGIGMTKADLINNLGTIAKSGTKAFMEALQAGADISMIGQFGVGFYSAYLVAEK VTVITKHNDDEQYAWESSAGGSFTVRTDTGEPMGRGTKVILHLKEDQTEYLEERRIKEIVKKHSQFIGYPITLFVEKERD KEVSDDEAE MGSSHHHHHHSSGLVPRGSHMDQPMEEEEVETFAFQAEIAQLMSLIINTFYSNKEIFLRELISNSSDALDKIRYESLTDP SKLDSGKELHINLIPNKQDRTLTIVDTGIGMTKADLINNLGTIAKSGTKAFMEALQAGADISMIGQFGVGFYSAYLVAEK VTVITKHNDDEQYAWESSAGGSFTVRTDTGEPMGRGTKVILHLKEDQTEYLEERRIKEIVKKHSQFIGYPITLFVEKERD KEVSDDEAE A polypeptide(L) n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n HUMAN sample 9606 HOMO SAPIENS 469008 ESCHERICHIA COLI BL21(DE3) 1.99 38.24 NONE repository Initial release Refinement description Structure summary Version format compliance 1 0 2010-09-01 1 1 2016-12-14 HUMAN HSP90 WITH 4-(4-(2,3-DIHYDRO- BENZOL(1,4)DIOXIN-6-YL)-5-METHYL-1H- PYRAZOL-3-YL)-6-ETHYL-BENZENE-1,3-DIOL HUMAN HSP90 GELDANAMYCIN-BINDING DOMAIN, "OPEN " CONFORMATION HUMAN HSP90-ALPHA WITH 8-BENZO[1,3] DIOXOL-,5-YLMETHYL-9-BUTYL-9H-PURIN-6- YLAMINE HSP90 N-TERMINAL DOMAIN BOUND TO ADP-MG NOVEL, POTENT SMALL MOLECULE INHIBITORS OF THE MOLECULAR CHAPERONE HSP90 DISCOVERED THROUGH STRUCTURE-BASED DESIGN HUMAN HSP90 IN COMPLEX WITH 17-DESMETHOXY- 17-N,N-DIMETHYLAMINOETHYLAMINO-GELDANAMYCIN ORALLY ACTIVE 2-AMINO THIENOPYRIMIDINE INHIBITORS OF THE HSP90 CHAPERONE HUMAN HSP90-ALPHA WITH 9-BUTYL-8-(3- TRIMETHOXY-BENZYL)-9H-PURIN-6YLAMINE SOLUTION STRUCTURE OF THE TPR DOMAIN FROM PROTEIN PHOSPHATASE 5 IN COMPLEX WITH HSP90 DERIVED PEPTIDE ORALLY ACTIVE 2-AMINO THIENOPYRIMIDINE INHIBITORS OF THE HSP90 CHAPERONE INHIBITION OF THE HSP90 MOLECULAR CHAPERONE IN VITRO AND IN VIVO BY NOVEL, SYNTHETIC , POTENT RESORCINYLIC PYRAZOLE, ISOXAZOLE AMIDE ANALOGS ORALLY ACTIVE 2-AMINO THIENOPYRIMIDINE INHIBITORS OF THE HSP90 CHAPERONE NOVEL, POTENT SMALL MOLECULE INHIBITORS OF THE MOLECULAR CHAPERONE HSP90 DISCOVERED THROUGH STRUCTURE-BASED DESIGN HUMAN HSP90 GELDANAMYCIN-BINDING DOMAIN, " CLOSED" CONFORMATION STRUCTRE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND HUMAN HSP90-ALPHA WITH 8-(2,5-DIMETHOXY- BENZYL)-2-FLUORO-9H-PURIN-6-YLAMINE STRUCTURE-BASED DISCOVERY OF A NEW CLASS OF HSP90 INHIBITORS HUMAN HSP90 WITH 4-CHLORO-6-(4-(4-(4- METHANESULPHONYL-BENZYL)-PIERAZIN-1-YL)-1H- PYRAZOL-3-YL)-BENZENE-1,3-DIOL HUMAN HSP90 WITH 4-CHLORO-6-(4-PIPERAZIN- 1-YL-1H-PYRAZOL-3-YL)-BENZENE-1,2-DIOL HUMAN HSP90-ALPHA WITH 8-(2-CHLORO-3,4, 5-TRIMETHOXY-BENZYL)-2-FLUORO-9-PENT-4- YLNYL-9H-PURIN-6-YLAMINE CRYSTAL STRUCTURE OF HUMAN HSP90ALPHA COMPLEXED WITHDIHYDROXYPHENYLPYRAZOLES HUMAN HSP90-ALPHA WITH 8-(2,5-DIMETHOXY- BENZYL)-2-FLUORO-9-PENT-9H-PURIN-6- YLAMINE HUMAN HSP90-ALPHA WITH 9-BUTYL-8-(2- CHLORO-3,4,5-TRIMETHOXY-BENZYL)-9H-PURIN- 6-YLAMINE 3-(5-CHLORO-2,4-DIHYDROXYPHENYL)-PYRAZOLE- 4-CARBOXAMIDES AS INHIBITORS OF THE HSP90 MOLECULAR CHAPERONE STRUCTURE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND ORALLY ACTIVE 2-AMINO THIENOPYRIMIDINE INHIBITORS OF THE HSP90 CHAPERONE HUMAN HSP90-ALPHA WITH 9-BUTYL-8-(3,4, 5-TRIMETHOXY-BENZYL)-9H-PURIN-6-YLAMINE 4,5 DIARYL ISOXAZOLE HSP90 CHAPERONE INHIBITORS: POTENTIAL THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER ORALLY ACTIVE 2-AMINO THIENOPYRIMIDINE INHIBITORS OF THE HSP90 CHAPERONE 4,5 DIARYL ISOXAZOLE HSP90 CHAPERONE INHIBITORS: POTENTIAL THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER CRYSTAL STRUCTURE OF HUMAN HSP90ALPHA COMPLEXED WITHDIHYDROXYPHENYLPYRAZOLES CRYSTAL STRUCTURE OF THE CHIP U-BOX E3 UBIQUITIN LIGASE STRUCTURE OF HUMAN HSP90-ALPHA BOUND TO THE POTENT WATERSOLUBLE INHIBITOR PU-H71 STRUCTURE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND HUMAN HSP90-ALPHA WITH 9-BUTYL-8-(2,5- DIMETHOXY-BENZYL)-2-FLUORO-9H-PURIN-6- YLAMINE HUMAN HSP90-ALPHA WITH 8-BENZO[1,3] DIOXOL-,5-YLMETHYL-9-BUTYL-2-FLUORO-9H- PURIN-6-YLAMINE HUMAN HSP90 WITH 5-(5-CHLORO-2,4- DIHYDROXY-PHENYL)-4-PIPERAZIN-1-YL-2H- PYRAZOLE-3-CARBOXYLIC ACID ETHYLAMIDE STRUCTURE OF HUMAN HSP90-ALPHA BOUND TO THE POTENT WATERSOLUBLE INHIBITOR PU-H64 STRUCTURE-ACTIVITY RELATIONSHIPS IN PURINE- BASED INHIBITOR BINDING TO HSP90 ISOFORMS HUMAN HSP90-ALPHA WITH 8-(2-CHLORO-3,4, 5-TRIMETHOXY-BENZYL)-9-PENT-4-YLNYL-9H- PURIN-6-YLAMINE ORALLY ACTIVE 2-AMINO THIENOPYRIMIDINE INHIBITORS OF THE HSP90 CHAPERONE STRUCTURE OF HSP90 WITH AN INHIBITOR BOUND CRYSTAL STRUCTURES OF HUMAN HSP90ALPHA COMPLEXED WITHDIHYDROXYPHENYLPYRAZOLES HUMAN HSP90-ALPHA WITH 9-BUTYL-8-(2,5- DIMETHOXY-BENZYL)-9H-PURIN-6-YLAMINE HUMAN HSP90-ALPHA WITH 9-BUTYL-8-(4- METHOXY-BENZYL)-9H-PURIN-6-YLAMINE GELDANAMYCIN BOUND TO THE HSP90 GELDANAMYCIN- BINDING DOMAIN HSP90 ALPHA ATPASE DOMAIN WITH BOUND SMALL MOLECULE FRAGMENT 3-(5-CHLORO-2,4-DIHYDROXYPHENYL)-PYRAZOLE- 4-CARBOXAMIDES AS INHIBITORS OF THE HSP90 MOLECULAR CHAPERONE ORALLY ACTIVE 2-AMINO THIENOPYRIMIDINE INHIBITORS OF THE HSP90 CHAPERONE STRUCTRE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND PDBE Y PDBE 2010-05-10 REL WOE 4-CHLORO-6-(2-METHOXYPHENYL)PYRIMIDIN-2-AMINE HOH water WOE 1224 2 WOE WOE 1224 A HOH 2001 3 HOH HOH 2001 A HOH 2002 3 HOH HOH 2002 A HOH 2003 3 HOH HOH 2003 A HOH 2004 3 HOH HOH 2004 A HOH 2005 3 HOH HOH 2005 A HOH 2006 3 HOH HOH 2006 A HOH 2007 3 HOH HOH 2007 A HOH 2008 3 HOH HOH 2008 A HOH 2009 3 HOH HOH 2009 A HOH 2010 3 HOH HOH 2010 A HOH 2011 3 HOH HOH 2011 A HOH 2012 3 HOH HOH 2012 A HOH 2013 3 HOH HOH 2013 A HOH 2014 3 HOH HOH 2014 A HOH 2015 3 HOH HOH 2015 A HOH 2016 3 HOH HOH 2016 A HOH 2017 3 HOH HOH 2017 A HOH 2018 3 HOH HOH 2018 A HOH 2019 3 HOH HOH 2019 A HOH 2020 3 HOH HOH 2020 A HOH 2021 3 HOH HOH 2021 A HOH 2022 3 HOH HOH 2022 A HOH 2023 3 HOH HOH 2023 A HOH 2024 3 HOH HOH 2024 A HOH 2025 3 HOH HOH 2025 A HOH 2026 3 HOH HOH 2026 A HOH 2027 3 HOH HOH 2027 A HOH 2028 3 HOH HOH 2028 A HOH 2029 3 HOH HOH 2029 A HOH 2030 3 HOH HOH 2030 A HOH 2031 3 HOH HOH 2031 A HOH 2032 3 HOH HOH 2032 A HOH 2033 3 HOH HOH 2033 A HOH 2034 3 HOH HOH 2034 A HOH 2035 3 HOH HOH 2035 A HOH 2036 3 HOH HOH 2036 A HOH 2037 3 HOH HOH 2037 A HOH 2038 3 HOH HOH 2038 A HOH 2039 3 HOH HOH 2039 A HOH 2040 3 HOH HOH 2040 A HOH 2041 3 HOH HOH 2041 A HOH 2042 3 HOH HOH 2042 A HOH 2043 3 HOH HOH 2043 A HOH 2044 3 HOH HOH 2044 A HOH 2045 3 HOH HOH 2045 A HOH 2046 3 HOH HOH 2046 A HOH 2047 3 HOH HOH 2047 A HOH 2048 3 HOH HOH 2048 A HOH 2049 3 HOH HOH 2049 A HOH 2050 3 HOH HOH 2050 A HOH 2051 3 HOH HOH 2051 A HOH 2052 3 HOH HOH 2052 A HOH 2053 3 HOH HOH 2053 A HOH 2054 3 HOH HOH 2054 A HOH 2055 3 HOH HOH 2055 A HOH 2056 3 HOH HOH 2056 A HOH 2057 3 HOH HOH 2057 A HOH 2058 3 HOH HOH 2058 A HOH 2059 3 HOH HOH 2059 A HOH 2060 3 HOH HOH 2060 A HOH 2061 3 HOH HOH 2061 A HOH 2062 3 HOH HOH 2062 A HOH 2063 3 HOH HOH 2063 A HOH 2064 3 HOH HOH 2064 A HOH 2065 3 HOH HOH 2065 A HOH 2066 3 HOH HOH 2066 A HOH 2067 3 HOH HOH 2067 A HOH 2068 3 HOH HOH 2068 A HOH 2069 3 HOH HOH 2069 A HOH 2070 3 HOH HOH 2070 A HOH 2071 3 HOH HOH 2071 A HOH 2072 3 HOH HOH 2072 A HOH 2073 3 HOH HOH 2073 A HOH 2074 3 HOH HOH 2074 A HOH 2075 3 HOH HOH 2075 A HOH 2076 3 HOH HOH 2076 A HOH 2077 3 HOH HOH 2077 A HOH 2078 3 HOH HOH 2078 A HOH 2079 3 HOH HOH 2079 A HOH 2080 3 HOH HOH 2080 A HOH 2081 3 HOH HOH 2081 A HOH 2082 3 HOH HOH 2082 A HOH 2083 3 HOH HOH 2083 A HOH 2084 3 HOH HOH 2084 A HOH 2085 3 HOH HOH 2085 A HOH 2086 3 HOH HOH 2086 A HOH 2087 3 HOH HOH 2087 A HOH 2088 3 HOH HOH 2088 A HOH 2089 3 HOH HOH 2089 A HOH 2090 3 HOH HOH 2090 A HOH 2091 3 HOH HOH 2091 A HOH 2092 3 HOH HOH 2092 A HOH 2093 3 HOH HOH 2093 A HOH 2094 3 HOH HOH 2094 A HOH 2095 3 HOH HOH 2095 A HOH 2096 3 HOH HOH 2096 A HOH 2097 3 HOH HOH 2097 A HOH 2098 3 HOH HOH 2098 A HOH 2099 3 HOH HOH 2099 A HOH 2100 3 HOH HOH 2100 A HOH 2101 3 HOH HOH 2101 A HOH 2102 3 HOH HOH 2102 A HOH 2103 3 HOH HOH 2103 A HOH 2104 3 HOH HOH 2104 A HOH 2105 3 HOH HOH 2105 A HOH 2106 3 HOH HOH 2106 A HOH 2107 3 HOH HOH 2107 A HOH 2108 3 HOH HOH 2108 A HOH 2109 3 HOH HOH 2109 A HOH 2110 3 HOH HOH 2110 A HOH 2111 3 HOH HOH 2111 A HOH 2112 3 HOH HOH 2112 A HOH 2113 3 HOH HOH 2113 A n 1 -12 A n 2 -11 A n 3 -10 A n 4 -9 A n 5 -8 A n 6 -7 A n 7 -6 A n 8 -5 A n 9 -4 A n 10 -3 A n 11 -2 A n 12 -1 A n 13 0 A n 14 1 A n 15 2 A n 16 3 A n 17 4 A n 18 5 A n 19 6 A n 20 7 A n 21 8 A n 22 9 A n 23 10 A PRO 11 n 24 PRO 11 A MET 12 n 25 MET 12 A GLU 13 n 26 GLU 13 A GLU 14 n 27 GLU 14 A GLU 15 n 28 GLU 15 A GLU 16 n 29 GLU 16 A VAL 17 n 30 VAL 17 A GLU 18 n 31 GLU 18 A THR 19 n 32 THR 19 A PHE 20 n 33 PHE 20 A ALA 21 n 34 ALA 21 A PHE 22 n 35 PHE 22 A GLN 23 n 36 GLN 23 A ALA 24 n 37 ALA 24 A GLU 25 n 38 GLU 25 A ILE 26 n 39 ILE 26 A ALA 27 n 40 ALA 27 A GLN 28 n 41 GLN 28 A LEU 29 n 42 LEU 29 A MET 30 n 43 MET 30 A SER 31 n 44 SER 31 A LEU 32 n 45 LEU 32 A ILE 33 n 46 ILE 33 A ILE 34 n 47 ILE 34 A ASN 35 n 48 ASN 35 A THR 36 n 49 THR 36 A PHE 37 n 50 PHE 37 A TYR 38 n 51 TYR 38 A SER 39 n 52 SER 39 A ASN 40 n 53 ASN 40 A LYS 41 n 54 LYS 41 A GLU 42 n 55 GLU 42 A ILE 43 n 56 ILE 43 A PHE 44 n 57 PHE 44 A LEU 45 n 58 LEU 45 A ARG 46 n 59 ARG 46 A GLU 47 n 60 GLU 47 A LEU 48 n 61 LEU 48 A ILE 49 n 62 ILE 49 A SER 50 n 63 SER 50 A ASN 51 n 64 ASN 51 A SER 52 n 65 SER 52 A SER 53 n 66 SER 53 A ASP 54 n 67 ASP 54 A ALA 55 n 68 ALA 55 A LEU 56 n 69 LEU 56 A ASP 57 n 70 ASP 57 A LYS 58 n 71 LYS 58 A ILE 59 n 72 ILE 59 A ARG 60 n 73 ARG 60 A TYR 61 n 74 TYR 61 A GLU 62 n 75 GLU 62 A SER 63 n 76 SER 63 A LEU 64 n 77 LEU 64 A THR 65 n 78 THR 65 A ASP 66 n 79 ASP 66 A PRO 67 n 80 PRO 67 A SER 68 n 81 SER 68 A LYS 69 n 82 LYS 69 A LEU 70 n 83 LEU 70 A ASP 71 n 84 ASP 71 A SER 72 n 85 SER 72 A GLY 73 n 86 GLY 73 A LYS 74 n 87 LYS 74 A GLU 75 n 88 GLU 75 A LEU 76 n 89 LEU 76 A HIS 77 n 90 HIS 77 A ILE 78 n 91 ILE 78 A ASN 79 n 92 ASN 79 A LEU 80 n 93 LEU 80 A ILE 81 n 94 ILE 81 A PRO 82 n 95 PRO 82 A ASN 83 n 96 ASN 83 A LYS 84 n 97 LYS 84 A GLN 85 n 98 GLN 85 A ASP 86 n 99 ASP 86 A ARG 87 n 100 ARG 87 A THR 88 n 101 THR 88 A LEU 89 n 102 LEU 89 A THR 90 n 103 THR 90 A ILE 91 n 104 ILE 91 A VAL 92 n 105 VAL 92 A ASP 93 n 106 ASP 93 A THR 94 n 107 THR 94 A GLY 95 n 108 GLY 95 A ILE 96 n 109 ILE 96 A GLY 97 n 110 GLY 97 A MET 98 n 111 MET 98 A THR 99 n 112 THR 99 A LYS 100 n 113 LYS 100 A ALA 101 n 114 ALA 101 A ASP 102 n 115 ASP 102 A LEU 103 n 116 LEU 103 A ILE 104 n 117 ILE 104 A ASN 105 n 118 ASN 105 A ASN 106 n 119 ASN 106 A LEU 107 n 120 LEU 107 A GLY 108 n 121 GLY 108 A THR 109 n 122 THR 109 A ILE 110 n 123 ILE 110 A ALA 111 n 124 ALA 111 A LYS 112 n 125 LYS 112 A SER 113 n 126 SER 113 A GLY 114 n 127 GLY 114 A THR 115 n 128 THR 115 A LYS 116 n 129 LYS 116 A ALA 117 n 130 ALA 117 A PHE 118 n 131 PHE 118 A MET 119 n 132 MET 119 A GLU 120 n 133 GLU 120 A ALA 121 n 134 ALA 121 A LEU 122 n 135 LEU 122 A GLN 123 n 136 GLN 123 A ALA 124 n 137 ALA 124 A GLY 125 n 138 GLY 125 A ALA 126 n 139 ALA 126 A ASP 127 n 140 ASP 127 A ILE 128 n 141 ILE 128 A SER 129 n 142 SER 129 A MET 130 n 143 MET 130 A ILE 131 n 144 ILE 131 A GLY 132 n 145 GLY 132 A GLN 133 n 146 GLN 133 A PHE 134 n 147 PHE 134 A GLY 135 n 148 GLY 135 A VAL 136 n 149 VAL 136 A GLY 137 n 150 GLY 137 A PHE 138 n 151 PHE 138 A TYR 139 n 152 TYR 139 A SER 140 n 153 SER 140 A ALA 141 n 154 ALA 141 A TYR 142 n 155 TYR 142 A LEU 143 n 156 LEU 143 A VAL 144 n 157 VAL 144 A ALA 145 n 158 ALA 145 A GLU 146 n 159 GLU 146 A LYS 147 n 160 LYS 147 A VAL 148 n 161 VAL 148 A THR 149 n 162 THR 149 A VAL 150 n 163 VAL 150 A ILE 151 n 164 ILE 151 A THR 152 n 165 THR 152 A LYS 153 n 166 LYS 153 A HIS 154 n 167 HIS 154 A ASN 155 n 168 ASN 155 A ASP 156 n 169 ASP 156 A ASP 157 n 170 ASP 157 A GLU 158 n 171 GLU 158 A GLN 159 n 172 GLN 159 A TYR 160 n 173 TYR 160 A ALA 161 n 174 ALA 161 A TRP 162 n 175 TRP 162 A GLU 163 n 176 GLU 163 A SER 164 n 177 SER 164 A SER 165 n 178 SER 165 A ALA 166 n 179 ALA 166 A GLY 167 n 180 GLY 167 A GLY 168 n 181 GLY 168 A SER 169 n 182 SER 169 A PHE 170 n 183 PHE 170 A THR 171 n 184 THR 171 A VAL 172 n 185 VAL 172 A ARG 173 n 186 ARG 173 A THR 174 n 187 THR 174 A ASP 175 n 188 ASP 175 A THR 176 n 189 THR 176 A GLY 177 n 190 GLY 177 A GLU 178 n 191 GLU 178 A PRO 179 n 192 PRO 179 A MET 180 n 193 MET 180 A GLY 181 n 194 GLY 181 A ARG 182 n 195 ARG 182 A GLY 183 n 196 GLY 183 A THR 184 n 197 THR 184 A LYS 185 n 198 LYS 185 A VAL 186 n 199 VAL 186 A ILE 187 n 200 ILE 187 A LEU 188 n 201 LEU 188 A HIS 189 n 202 HIS 189 A LEU 190 n 203 LEU 190 A LYS 191 n 204 LYS 191 A GLU 192 n 205 GLU 192 A ASP 193 n 206 ASP 193 A GLN 194 n 207 GLN 194 A THR 195 n 208 THR 195 A GLU 196 n 209 GLU 196 A TYR 197 n 210 TYR 197 A LEU 198 n 211 LEU 198 A GLU 199 n 212 GLU 199 A GLU 200 n 213 GLU 200 A ARG 201 n 214 ARG 201 A ARG 202 n 215 ARG 202 A ILE 203 n 216 ILE 203 A LYS 204 n 217 LYS 204 A GLU 205 n 218 GLU 205 A ILE 206 n 219 ILE 206 A VAL 207 n 220 VAL 207 A LYS 208 n 221 LYS 208 A LYS 209 n 222 LYS 209 A HIS 210 n 223 HIS 210 A SER 211 n 224 SER 211 A GLN 212 n 225 GLN 212 A PHE 213 n 226 PHE 213 A ILE 214 n 227 ILE 214 A GLY 215 n 228 GLY 215 A TYR 216 n 229 TYR 216 A PRO 217 n 230 PRO 217 A ILE 218 n 231 ILE 218 A THR 219 n 232 THR 219 A LEU 220 n 233 LEU 220 A PHE 221 n 234 PHE 221 A VAL 222 n 235 VAL 222 A GLU 223 n 236 GLU 223 A LYS 224 n 237 LYS 224 A n 238 225 A n 239 226 A n 240 227 A n 241 228 A n 242 229 A n 243 230 A n 244 231 A n 245 232 A n 246 233 A n 247 234 A n 248 235 A n 249 236 A software_defined_assembly PISA 1 monomeric 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 1_555 x,y,z identity operation 0.0000000000 0.0000000000 0.0000000000 A N PHE 20 A N PHE 33 A O PHE 170 A O PHE 183 A N ARG 173 A N ARG 186 A O ALA 161 A O ALA 174 A N SER 164 A N SER 177 A O VAL 148 A O VAL 161 A N LYS 153 A N LYS 166 A O GLY 183 A O GLY 196 A N LEU 188 A N LEU 201 A O LEU 89 A O LEU 102 A N VAL 92 A N VAL 105 A O ASN 79 A O ASN 92 A N LEU 80 A N LEU 93 A O THR 219 A O THR 232 1 A CA LYS 224 A CA LYS 237 1 Y 1 A C LYS 224 A C LYS 237 1 Y 1 A O LYS 224 A O LYS 237 1 Y 1 A CB LYS 224 A CB LYS 237 1 Y 1 A CG LYS 224 A CG LYS 237 1 Y 1 A CD LYS 224 A CD LYS 237 1 Y 1 A CE LYS 224 A CE LYS 237 1 Y 1 A NZ LYS 224 A NZ LYS 237 1 Y 1 A MET -12 A MET 1 1 Y 1 A GLY -11 A GLY 2 1 Y 1 A SER -10 A SER 3 1 Y 1 A SER -9 A SER 4 1 Y 1 A HIS -8 A HIS 5 1 Y 1 A HIS -7 A HIS 6 1 Y 1 A HIS -6 A HIS 7 1 Y 1 A HIS -5 A HIS 8 1 Y 1 A HIS -4 A HIS 9 1 Y 1 A HIS -3 A HIS 10 1 Y 1 A SER -2 A SER 11 1 Y 1 A SER -1 A SER 12 1 Y 1 A GLY 0 A GLY 13 1 Y 1 A LEU 1 A LEU 14 1 Y 1 A VAL 2 A VAL 15 1 Y 1 A PRO 3 A PRO 16 1 Y 1 A ARG 4 A ARG 17 1 Y 1 A GLY 5 A GLY 18 1 Y 1 A SER 6 A SER 19 1 Y 1 A HIS 7 A HIS 20 1 Y 1 A MET 8 A MET 21 1 Y 1 A ASP 9 A ASP 22 1 Y 1 A GLN 10 A GLN 23 1 Y 1 A GLU 225 A GLU 238 1 Y 1 A ARG 226 A ARG 239 1 Y 1 A ASP 227 A ASP 240 1 Y 1 A LYS 228 A LYS 241 1 Y 1 A GLU 229 A GLU 242 1 Y 1 A VAL 230 A VAL 243 1 Y 1 A SER 231 A SER 244 1 Y 1 A ASP 232 A ASP 245 1 Y 1 A ASP 233 A ASP 246 1 Y 1 A GLU 234 A GLU 247 1 Y 1 A ALA 235 A ALA 248 1 Y 1 A GLU 236 A GLU 249 1 Y 1 A ASN 35 -95.30 35.13 1 A SER 72 -69.71 11.73 1 A ARG 87 72.81 46.41 1 A THR 94 -95.54 38.64 1 A ALA 166 76.30 -138.75 1 A GLU 178 -30.54 115.12 1 A ARG 182 -172.42 137.35 1 A PHE 213 -91.11 40.44 23.34 -3.02296482 0.00000000 7.97994950 2.51114933 0.00000000 0.51181549 0.3304 0.2029 0.2090 2.42 32.33 370 7610 4.9 88.65 RANDOM 1 THROUGHOUT 0.0 OTHER NONE 2.42 32.33 113 1807 16 0 1678 0.4497 0.2239 0.2327 2.57 43 947 990 9 4.34 88.65 37.996 2.45 32.51 2XDX 8264 0.0 0.12 1 2.4 92.1 refinement BUSTER-TNT 2.5.1 HEAT SHOCK PROTEIN HSP 90-ALPHA Structure of HSP90 with small molecule inhibitor bound 1 N N 2 N N 3 N N A GLN 23 A GLN 36 HELX_P A ASN 35 A ASN 48 1 1 13 A GLU 42 A GLU 55 HELX_P A LEU 64 A LEU 77 1 2 23 A ASP 66 A ASP 79 HELX_P A ASP 71 A ASP 84 5 3 6 A THR 99 A THR 112 HELX_P A LEU 107 A LEU 120 1 4 9 A GLY 114 A GLY 127 HELX_P A ALA 124 A ALA 137 1 5 11 A ASP 127 A ASP 140 HELX_P A GLY 135 A GLY 148 5 6 9 A VAL 136 A VAL 149 HELX_P A LEU 143 A LEU 156 5 7 8 A GLU 192 A GLU 205 HELX_P A LEU 198 A LEU 211 5 8 7 A GLU 199 A GLU 212 HELX_P A SER 211 A SER 224 1 9 13 CHAPERONE CHAPERONE, INHIBITOR, STRESS RESPONSE HS90A_HUMAN UNP 1 P07900 9 236 2XDX 9 236 P07900 A 1 22 249 1 expression tag MET -12 2XDX A P07900 UNP 1 1 expression tag GLY -11 2XDX A P07900 UNP 2 1 expression tag SER -10 2XDX A P07900 UNP 3 1 expression tag SER -9 2XDX A P07900 UNP 4 1 expression tag HIS -8 2XDX A P07900 UNP 5 1 expression tag HIS -7 2XDX A P07900 UNP 6 1 expression tag HIS -6 2XDX A P07900 UNP 7 1 expression tag HIS -5 2XDX A P07900 UNP 8 1 expression tag HIS -4 2XDX A P07900 UNP 9 1 expression tag HIS -3 2XDX A P07900 UNP 10 1 expression tag SER -2 2XDX A P07900 UNP 11 1 expression tag SER -1 2XDX A P07900 UNP 12 1 expression tag GLY 0 2XDX A P07900 UNP 13 1 expression tag LEU 1 2XDX A P07900 UNP 14 1 expression tag VAL 2 2XDX A P07900 UNP 15 1 expression tag PRO 3 2XDX A P07900 UNP 16 1 expression tag ARG 4 2XDX A P07900 UNP 17 1 expression tag GLY 5 2XDX A P07900 UNP 18 1 expression tag SER 6 2XDX A P07900 UNP 19 1 expression tag HIS 7 2XDX A P07900 UNP 20 1 expression tag MET 8 2XDX A P07900 UNP 21 8 anti-parallel anti-parallel anti-parallel anti-parallel anti-parallel anti-parallel parallel A GLU 18 A GLU 31 A ALA 21 A ALA 34 A SER 169 A SER 182 A THR 174 A THR 187 A GLN 159 A GLN 172 A SER 164 A SER 177 A ALA 145 A ALA 158 A LYS 153 A LYS 166 A GLY 183 A GLY 196 A LEU 190 A LEU 203 A THR 88 A THR 101 A ASP 93 A ASP 106 A ILE 78 A ILE 91 A ASN 83 A ASN 96 A ILE 218 A ILE 231 A LEU 220 A LEU 233 BINDING SITE FOR RESIDUE WOE A 1224 Software 13 A ASN 51 A ASN 64 13 1_555 A SER 52 A SER 65 13 1_555 A ALA 55 A ALA 68 13 1_555 A ASP 93 A ASP 106 13 1_555 A ILE 96 A ILE 109 13 1_555 A GLY 97 A GLY 110 13 1_555 A MET 98 A MET 111 13 1_555 A ASN 106 A ASN 119 13 1_555 A LEU 107 A LEU 120 13 1_555 A PHE 138 A PHE 151 13 1_555 A THR 184 A THR 197 13 1_555 A HOH 2029 C HOH 13 1_555 A HOH 2054 C HOH 13 1_555 4 P 1 21 1